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The clinical cost per approved new drug has increased more than 10 times in 20 years and was estimated to 
be $ 1,460 million in the 2000s. In addition, the success rate of therapeutic drugs targeting disorders of the 
central nervous system (CNS) is low, less than 10% mainly because of the lack of animal models reflecting the 
pathology of CNS disease in human. An estimation of effective dose of drugs, selection of appropriate patients 
based on mechanism of action and efficacy prediction in short-term trials by biomarkers expected to be 
potential options to increase the success rates of clinical trials for CNS-targeting drugs.  
Positron-emission tomography (PET) is a non-invasive imaging technology that allows quantification of 
physiological and pathological processes in living subjects. PET imaging could potentially provide a means to 
determine the occupancy of a target molecule in human brain by therapeutic inhibitors. This information 
obtained from in vivo PET scans can afford dose setting in clinical trials, which could lead to rational protocol 
design and following go/no-go decision. In addition, PET imaging could allow the patient stratification for the 
clinical trial and the efficacy evaluation of the drug by using the radiotracer as a diagnostic marker and a 
surrogate marker for efficacy, respectively. Given these factors, PET technology is expected to increase success 
rate of the clinical trial and save its cost. Because the above technologies require a PET radiotracer that binds a 
target molecule specifically, the development of radiotracers is also highly required.  
Endocannabinoid neurotransmission in the central and peripheral nervous systems is dependent on 
cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) and their endogenous fatty acid 
ligands. The primary endogenous ligands for CB1 and CB2 receptors are N-arachidonoyl ethanolamine (AEA), 
also known as anandamide, and 2-arachidonoylglycerol (2-AG). Both regulate multiple physiological processes 
in CNS, including pain, inflammation, appetite, memory, and emotion. AEA and 2-AG are biosynthesized by 
the phospholipase-catalyzed hydroxylation of membrane phospholipids and are rapidly inactivated by 
enzymatic hydrolysis after exerting physiological actions through the cannabinoid receptors. The degradation of 
these endocannabinoids is mainly mediated by fatty acid amide hydrolase (FAAH) and monoacylglycerol 
lipase (MAGL). 
MAGL is a cytosolic serine hydrolase that cleaves monoacylglycerols into fatty acids and glycerol. It is 
responsible for about85% of 2-AG hydrolysis. Thus, inhibition of MAGL increases 2-AG levels, leading to 
activation of endocannabinoid neurotransmission and consequent anti-nociceptive, anxiolytic, and anti-emetic 
responses. In addition, MAGL inhibition decreases arachidonic acid levels, resulting in anti-inflammatory and 
neuroprotection effects in the brain. Thus, MAGL could be a promising target for the treatment of 
neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington’s disease and 
neuropsychiatric disorders in which the endocannabinoid system and neuroinflammation have mechanistically 
been implicated. 
Several PET imaging agents for MAGL have been reported, and some of these compounds exhibit 
selectivity for MAGL and high uptake in the brains of rodents and non-human primates. However, all the 
agents reported bind to MAGL irreversibly, preventing quantification of binding components. Accordingly, I 
aimed to develop PET imaging agents that bind to MAGL selectively and reversibly. 
In this thesis, I present the development of novel PET imaging agents that bind to MAGL selectively and 
reversibly in chapter 2 and PET studies using the optimized MAGL radiotracer, [18F]T-401, for quantification of 
MAGL in the brain of rhesus monkey and its occupancy by a well-known MAGL inhibitor in chapter 3. 
 
CHAPTER 2: Design, Synthesis, and Evaluation of Novel Positron-Emission Tomography Imaging 
Agents for Monoacylglycerol Lipase (MAGL)
1 
 
Central nervous system PET imaging agents need not only high affinity and selectivity for the target in order 
to provide sufficient in vivo binding potential, but also desirable physicochemical and pharmacokinetic 
properties that allow efficient blood-brain barrier (BBB) penetration, low levels of undesirable nonspecific 
binding (NSB) and low level of brain penetrant radiometabolites. Considering these factors, I selected the 
recently identified piperazinyl pyrrolidin-2-one derivative 1 which binds to MAGL reversibly as a lead 
compound for the development of a new class of MAGL PET imaging agents. By tailoring the lipophilicity of 
the molecule to optimize nonspecific binding and blood-brain barrier permeability, I successfully identified two 
compounds (5 and 8) that show high uptake to regions enriched with MAGL in the wild-type (WT) mouse 
brain in ex vivo LC-MS/MS studies using unlabeled 5 and 8. The uptakes of these compounds were reduced in 
MAGL-knockout (KO) mice, demonstrating that the binding of compounds 5 and 8 in the mouse brain is 
highly specific to MAGL.  
[18F]5 and [18F]8 were synthesized by [18F]fluorination of the precursors with high radiochemical purity 
(>99%), and their radiochemical yields decay-corrected for cyclotron-produced [18F]fluoride were 21.7 ± 3.0% 
(n = 11) and 20.1 ± 4.6% (n = 3), respectively. Their molar activities were 391 ± 99 GBq/μmol for [18F]5 and 
191 ± 67 GBq/μmol for [18F]8 at the end of the synthesis.  
PET imaging of WT and MAGL-KO mice revealed that the highest uptake of [18F]5 and [18F]8 occurs in the 
frontal cortex, followed by the striatum and hippocampus, and the lowest radioactivity uptake is that in the 
midbrain. The uptakes of [18F]5 in all these regions peaks immediately after injection, and decreases to 10–20% 
of the maximum at 90 min. The kinetics of [18F]8 in the brain are slower than those of [18F]5, with its uptakes in 
the frontal cortex, hippocampus, and striatum peaking at ≈15 min, followed by a gradual decline in radioactivity 
to 40–60% of the maximum at 90 min. The differences in the pharmacokinetic properties of [18F]5 and [18F]8 in 
the mouse brain are consistent with the results of LC-MS/MS study, validating this ex vivo assay as a means for 
predicting in vivo profiles of compounds. In MAGL-KO mice, the uptakes of [18F]5 and [18F]8 were profoundly 
reduced compared with those for WT mice, and the radioactivity distribution is fairly uniform across these brain 
regions. In a rhesus monkey, [18F]5 (named [18F]T-401) showed adequate kinetics for PET quantification of 
MAGL, whereas the kinetics of [18F]8 in the brain were slower than those of [18F]5, and the radioactivity uptake 
in the frontal cortex did not reach pseudo-equilibrium within the 2-hour PET imaging session.  
 
 
CHAPTER 3: Quantification of MAGL and its Occupancy by an Exogenous Ligand in Rhesus 
Monkey Brains using [
18
F]T-401 and PET 
 
I have developed [18F]T-401 as a novel and selective PET imaging agent for MAGL in chapter 2, and 
reversible binding properties of this radiotracer is suitable for quantitative assays of MAGL. In this chapter, I 
aimed at determining an analytical method to quantify MAGL in the brain of rhesus monkey and its occupancy 
by an exogenous inhibitor JW642 by PET using [18F]T-401.  
  In a rhesus monkey, [18F]T-401 efficiently entered the brain with its uptake peaking at 5-15 min followed by 
a continuous washout from all brain regions over 120 min. The highest retention of [18F]T-401 was observed in 
the striatum, and frontal and occipital cortices in contrast with its lowest uptake in the brain stem. Regional 
time-activity curves were well described by a 2-tissue compartment model in consideration of the accumulation 
of a radiometabolite produced in the brain (2T+mCM). Metabolic analyses in mice also indicated the 
generation of a radiometabolite of [18F]T-401 in the brain, which supported the use of 2T+mCM for describing 
brain kinetics of [18F]T-401. This model yielded reliable estimates of a total distribution volume (VT) and the 
rank order of VT (neocortex > striatum > cerebellum > thalamus > hippocampus > pons) was consistent with 
known regional expressions of MAGL. Pretreatment of monkeys with JW642 resulted in a dose-dependent 
reduction of [18F]T-401 retentions in the brain, and Lassen’s graphical analysis of VT enabled determination of 
plasma JW642 concentration (126.1 ng/mL) inducing 50% occupancy of central MAGL. 
 
As shown above, I successfully developed [18F]T-401 as a novel, reversible, and selective PET radiotracer for 
MAGL. I also established an analytical method to quantify MAGL and its occupancy by an exogenous 
inhibitor in rhesus monkey brains using [18F]T-401-PET. Based on its favorable imaging properties, [18F]T-401 
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る。脳内 MAGL の可視化に適した可逆的結合性を示す PET トレーサーを開発できれば、
中枢 MAGL 標的治療薬の作用機序や受容体占有率の評価に PET イメージングを活用でき、
創薬の効率化が期待できる。そこで著者は、実用性の観点から 18F を標識核種とする MAGL
イメージングトレーサーの開発に取り組んだ。 





マウスに投与して脳内濃度の継時変化を LC-MS/MS で測定し、PET トレーサーとして好
ましい脳移行性を示すことを確認した。また、MAGL-KO マウスを用いることでその化合
物の脳集積は MAGL の発現に依存していることを明らかにした。これらの結果を踏まえ、
その 2 化合物の 18F 標識体を合成して MAGL-KO マウスおよびサルを用いた PET 実験を
行い、それらの脳内動態性を比較した。そしてより優れた脳内分布と動態性を示した化合




示すことを明らかにした。そして MAGL 阻害剤として知られる JW642 を用いて、その脳
内 MAGL への結合占有率を PET で測定することに成功した。 
 以上、本研究では計算化学を利用した薬物分子設計とその有機合成、in vitro 活性評価、
in vivo 動態評価、PET イメージングといった分子から生体に至るまでの創薬学的研究を
展開し、脳内 MAGL の画像化に適した PET トレーサーの開発に成功している。よってそ
の研究成果をまとめた本論文は、博士(薬科学)の学位論文として十分に相応しいと判断し、
合格と認める。 
